TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis

TMPRSS6 is a serine protease highly expressed in the liver. Its role in iron regulation was first reported in 2008 when mutations in TMPRSS6 were shown to be the cause of iron-refractory iron deficiency anemia (IRIDA) in humans and in mouse models. TMPRSS6 functions as a negative regulator of the ex...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2023-04, Vol.40 (4), p.1317-1333
Hauptverfasser: Ganz, Tomas, Nemeth, Elizabeta, Rivella, Stefano, Goldberg, Paul, Dibble, Andrew R., McCaleb, Michael L., Guo, Shuling, Monia, Brett P., Barrett, Terrance D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:TMPRSS6 is a serine protease highly expressed in the liver. Its role in iron regulation was first reported in 2008 when mutations in TMPRSS6 were shown to be the cause of iron-refractory iron deficiency anemia (IRIDA) in humans and in mouse models. TMPRSS6 functions as a negative regulator of the expression of the systemic iron-regulatory hormone hepcidin. Over the last decade and a half, growing understanding of TMPRSS6 biology and mechanism of action has enabled development of new therapeutic approaches for patients with diseases of erythropoiesis and iron homeostasis. ClinicalTrials.gov identifier NCT03165864.
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-022-02421-w